Delving into the Latest Updates on Nanjing Immunophage Biotech Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Immunophage Biotech is a pharmaceutical company based in China that specializes in the research and development of innovative medicines for the treatment of cancer, autoimmune diseases, and neurodegenerative disorders. The company was founded in 2016 and has its R&D center located in the Pujiang High-Tech Park in Shanghai. Their focus is on creating groundbreaking immune-regulating therapies that can improve patient outcomes.

Tags

Neoplasms

Immune System Diseases

Nervous System Diseases

Small molecule drug

Antibody

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	14
Nervous System Diseases	13
Neoplasms	9
Endocrinology and Metabolic Disease	7
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	12
Monoclonal antibody	6
Antibody	2
Chemical drugs	1

Top 5 Target	Count

GPR183(G protein-coupled receptor 183)	4
CCR8(C-C motif chemokine receptor 8)	3
CD38(Lymphocyte differentiation antigen CD38)	2
CD38 x Hydrolases x NAD+	1
GPR17(G protein-coupled receptor 17)	1

A部分-单剂量递增（SAD）主要目的：评价单剂量口服IPG8294的安全性和耐受性次要目的： 1.评价单剂量口服IPG8294的药代动力学（pharmacokinetics，PK）特征 2.评价食物对单剂量口服IPG8294的药代动力学的影响评价口服IPG8294对受试者生物标志物的影响 B部分-多剂量递增（MAD）主要目的：评价多剂量口服IPG8294的安全性和耐受性次要目的： 1.评价多剂量口服IPG8294的药代动力学（pharmacokinetics，PK）特征 2.评价口服IPG8294对受试者生物标志物的影响

[Translation]

Part A - Single Ascending Dose (SAD) Primary Objective: To evaluate the safety and tolerability of a single oral dose of IPG8294 Secondary Objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single oral dose of IPG8294 2. To evaluate the effect of food on the pharmacokinetics of a single oral dose of IPG8294 Evaluate the effect of oral IPG8294 on biomarkers of subjects Part B - Multiple Ascending Dose (MAD) Primary Objective: To evaluate the safety and tolerability of multiple oral doses of IPG8294 Secondary Objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of multiple oral doses of IPG8294 2. To evaluate the effect of oral IPG8294 on biomarkers of subjects

Start Date01 Jul 2025

Sponsor / Collaborator

Nanjing Immunophage Biotech Co. Ltd.

NCT06717815

/ RecruitingPhase 1/2

A Multi-center, Multi-dose Phase Ib/IIa Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Impact on Biomarkers of IPG11406 in Patients With Lupus Nephritis

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

Start Date25 Feb 2025

Sponsor / Collaborator

Nanjing Immunophage Biotech Co. Ltd.

NCT06212076

/ RecruitingPhase 1/2

A Phase I/II, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Characteristics and Initial Anti-tumor Activity of IPG1094 in Patients With Advanced Solid Tumors

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

Start Date11 Jul 2024

Sponsor / Collaborator

Nanjing Immunophage Biotech Co. Ltd.

100 Clinical Results associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

100 Deals associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

100 Translational Medicine associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

12

4

Preclinical

IND Application

1

Phase 1

Phase 2

3

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IPG-1094 ( MIF )	Lupus Nephritis More	Phase 2
IPG-11406 ( GPR183 )	Lupus Nephritis More	Phase 2
IPG-7236 ( CCR8 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
IPG-8294 ( CD38 x Hydrolases x NAD+ )	Alzheimer Disease More	Phase 1
IPG0521 ( CCR8 )	Solid tumor More	IND Application